Akero Therapeutics Files 8-K
| Field | Detail |
|---|---|
| Company | Akero Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financials
Related Tickers: AKRO
TL;DR
AKRO filed an 8-K for financial updates, no major news yet.
AI Summary
Akero Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these categories.
Why It Matters
This filing indicates Akero Therapeutics is providing updates on its financial condition and operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and exhibits, not announcing significant new risks or events.
Key Players & Entities
- Akero Therapeutics, Inc. (company) — Registrant
- May 12, 2025 (date) — Date of earliest event reported
- 601 Gateway Boulevard, Suite 350 (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices
- 001-38944 (other) — Commission File Number
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures are not detailed in the provided text.
When was this 8-K filed?
The filing was made on May 12, 2025.
What is the primary business of Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. is in the 'Pharmaceutical Preparations' industry, SIC code 2834.
Where are Akero Therapeutics' principal executive offices located?
The principal executive offices are located at 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080.
What is the Commission File Number for Akero Therapeutics, Inc.?
The Commission File Number is 001-38944.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding Akero Therapeutics, Inc..